A condition defined by a committee, with no single test — and the genetics still found something. The strongest locus reached an odds ratio of 0.67, which for a common variant is large.
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
Polycystic ovary syndrome is common, it affects fertility, metabolism and skin, and it does not have a defining test. Diagnosis is made from a combination of irregular or absent ovulation, clinical or biochemical signs of excess androgens, and the appearance of the ovaries on ultrasound — with other causes excluded.
A syndrome defined by a checklist is a hard thing to run genetics on. The cases are not guaranteed to be one biological thing.
A 2011 study in Han Chinese women began with 744 cases and 895 controls and replicated in two independent cohorts — 2,840 cases and 5,012 controls from northern China, then 498 cases and 780 controls from southern and central China.
Three loci came through with strong evidence:
Odds ratios of 0.67 and 1.34 are substantial for common variants. Most common-variant findings sit near 1.05. Whatever the diagnostic fuzziness, something real is underneath.
The other position on this page, rs10818854, is in DENND1A at the 9q33.3 locus. The study's own index SNP for that region is rs2479106; ours is a different marker in the same gene, and this page does not transfer the published odds ratio onto it.
DENND1A is involved in how cells take receptors back in from their surface — a general piece of cell machinery rather than anything reproductive. And the clinical picture supports the wider reading: insulin resistance, weight, and cardiovascular risk are part of this condition, not complications bolted onto it.
PCOS is a metabolic condition that presents through the reproductive system, and the genetics reads that way too.
All three cohorts were Han Chinese. That matters in both directions: it is a large, well-replicated study in a population that GWAS has historically under-served, and it is a single ancestry, so the effect sizes should not be assumed to transfer unchanged.
Not diagnose. PCOS is diagnosed on the clinical criteria, and no genotype substitutes for them or predicts who will develop it.
What the genetics does support is a change in how the condition is framed. Long treated as a gynaecological problem to be managed cycle by cycle, PCOS looks — from the loci and from the clinical course — like a systemic metabolic condition. That framing changes what gets monitored over a lifetime, and it is a change worth more to patients than a risk score would be.
Positions joined since this page was written
What this is The text above discusses the variants this page was written around. Since then the catalogue has joined 3 more positions to it, by shared trait or shared paper. They are listed here by the paper each came from; the text does not describe them, and each variant page carries that study's own record.
Burns K et al. 2024, BMC genomics rs12000707 (DENND1A), rs569675099 (DENND1A) — PMID:38408933
Liu Q et al. 2022, Diabetologia rs9844212 (ADCY5) — PMID:35771237
2025-11-04 · Multi-ancestry genome-wide association analyses of polycystic ovary syndrome. Nature Genetics. 2025. DOI:10.1038/s41588-025-02393-x
Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women and highly heritable, but its polygenic architecture had remained poorly mapped. This study combined a GWAS of 12,419 Chinese women with PCOS and 34,235 controls with a multi-ancestry meta-analysis including up to 13,773 European cases and 411,088 controls, identifying 94 independent loci, 73 of them newly reported -- a substantial expansion of known PCOS genetics. Despite different evolutionary histories, Chinese and European ancestries showed substantial genetic overlap, a genuine cross-population validation. Functional analysis prioritized anti-Müllerian hormone (AMH) as a disease-causing gene and implicated peroxisome proliferator-activated receptor gamma (PPARG) signaling -- notably, PPARG is the target of the thiazolidinedione class of diabetes drugs, giving this finding direct pharmacological relevance to PCOS's well-known metabolic overlap with insulin resistance. The study specifically identified granulosa cells (the ovarian cells surrounding developing eggs) as a particularly important cell type in PCOS development. Its genetics-driven drug discovery analysis flagged multiple existing drug targets and repurposing candidates. This site's polycystic ovary syndrome page carries 23 variants; AMH, PPARG and the other newly reported loci are not currently among them.
2025-08-01 · Genomic Correlations, Shared Loci, and Drug Targets Between Polycystic Ovary Syndrome and Asthma: Insights From Genome-wide Association Analysis. Journal of Clinical Endocrinology and Metabolism. 2025. DOI:10.1210/clinem/dgaf276
PCOS and asthma co-occur more than chance predicts -- a shared gene, ERBB3, may explain why
Observational studies had noted that polycystic ovary syndrome (PCOS) and asthma-related traits co-occur, but it was unclear whether this reflects shared genetics or just observational bias (e.g., obesity affecting both independently). Combining 10,074 PCOS cases with asthma-related traits from UK Biobank and FinnGen, this study found a genuine positive genetic correlation between PCOS and asthma. Along the way, it found 3 novel genome-wide significant loci for asthma subtypes specifically (2 for allergic asthma, 1 for childhood asthma) -- a real addition to asthma genetics discovered as a byproduct of the cross-condition analysis. Pleiotropy analysis identified 5 shared causal regions spanning 13 genes, with ERBB3 emerging as a candidate central gene for the shared biology between the two conditions. Tissue enrichment analysis found relevant shared gene expression in the hypothalamo-pituitary, endocrine, respiratory and urogenital systems -- a genuinely cross-system biological story, not just statistical coincidence. Drug-repurposing analysis flagged anakinra (an existing anti-inflammatory drug) and artenimol as candidates worth investigating for PCOS-asthma comorbidity specifically. This site's polycystic ovary syndrome page carries 23 variants and asthma page carries variants from earlier 2026 findings; ERBB3 is not currently on either.
2026-04-23 · Moolhuijsen LME, Zhu J, Mullin BH, et al., Nature Genetics
Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
A genetic study of 544,513 people expands the known PCOS loci from 16 to 29 and identifies 31 associated plasma proteins. Many risk-increasing loci were also associated with later age at menopause -- read by the authors as reproductive longevity from a larger or longer-lasting oocyte supply -- and hormonal regulation, through metabolic and reproductive features, was emphasized throughout. A polygenic risk score was associated with adverse cardiometabolic outcomes, with testosterone and body mass index mattering differently in women and men; and despite oligo-anovulation being a feature of PCOS, PCOS susceptibility had no impact on childlessness. The authors' summary: balanced pleiotropic influences on fertility in women, and life-long adverse metabolic consequences in both sexes. PMID:42026183.
Source. Chen et al. (Nat Genet 2011) conducted a genome-wide association study of PCOS in Han Chinese. The discovery set comprised 744 cases and 895 controls; replication used 2,840 cases and 5,012 controls from northern Han Chinese and 498 cases and 780 controls from southern and central Han Chinese. Three loci showed strong evidence of association: 2p16.3 (rs13405728, meta P = 7.55 × 10⁻²¹, OR 0.71), 2p21 (rs13429458, meta P = 1.73 × 10⁻²³, OR 0.67) and 9q33.3 (rs2479106, meta P = 8.12 × 10⁻¹⁹, OR 1.34).
Positions listed here. rs13429458 is the study's own 2p21 index SNP. rs10818854 was recorded by the collector against DENND1A at the 9q33.3 locus and is not the index SNP named in the abstract for that region; the odds ratio above belongs to rs2479106 and is not transferred to it here.
Diagnosis. Made on established consensus criteria requiring a combination of oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology, with exclusion of other causes of hyperandrogenism and ovulatory dysfunction. There is no diagnostic laboratory test and no genotype has diagnostic or predictive use.
Metabolic dimension. Insulin resistance, impaired glucose tolerance and adverse cardiometabolic risk profiles are recognised features rather than incidental comorbidities, and long-term management reflects that.
Population. Discovery and both replication cohorts were Han Chinese. Effect sizes and marker–allele relationships should not be assumed to transfer to other ancestries without direct study.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Polycystic Ovary Syndrome comes down to these specific, well-studied positions — not a diagnosis. 26 positions are linked to this page; the ones this page's own text discusses are shown first.
DENND1A · rs3945628
See detailed info →ADCY5 · rs9844212
See detailed info →The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 23 of 26 linked studies with a resolved discovery ancestry.
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Polycystic Ovary Syndrome. MyGeneLog™. https://www.mygenelog.com/conditions/polycystic-ovary-syndrome
It is a fair objection, and the answer is that the signal came through anyway. Fuzzy case definitions weaken a study, they do not fabricate findings — and this one replicated in two independent cohorts at odds ratios far larger than common-variant genetics usually produces.
No. Diagnosis rests on the clinical criteria: ovulation, androgen excess and ovarian appearance, with other causes excluded. No genotype substitutes for them, and none predicts who will develop the condition.
Because insulin resistance and cardiometabolic risk are features of it rather than complications of it, and the genes found point at general cellular machinery rather than at anything reproductive. It presents through the reproductive system; it is not confined to it.
Partly, and honestly nobody should promise more than that. It is a large and well-replicated study in a population genetics has under-served, and it is one ancestry. Effect sizes and the relationship between a marker and the causal variant can both differ elsewhere.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.